CD20×CD3 bispecific T-cell–engaging antibody that redirects T cells to kill malignant CD20-positive B cells.
CD20×CD3 bispecific antibody that simultaneously binds CD3 on T cells and CD20 on B cells, forming an immunologic synapse that activates and redirects T cells to kill CD20-positive B cells via CTL-mediated cytotoxicity.
NO
INDIRECT
Glofitamab binds CD3 to activate and redirect T cells, which then kill CD20+ B cells via CTL-mediated perforin/granzyme apoptosis; CD3+ T cells themselves are not targeted for killing.
Glycoengineered type II anti-CD20 monoclonal antibody with enhanced ADCC/ADCP and direct cell-death activity; used as a pre-dose with glofitamab.
Glycoengineered, humanized type II anti‑CD20 IgG1 that binds CD20 on B cells; afucosylated Fc increases affinity for FcγRIIIa, enhancing ADCC and ADCP, and it induces strong direct, caspase‑independent cell death of CD20+ B cells (with limited complement activation).
YES
DIRECT
Binds CD20 on B cells and triggers effector functions via its Fc (enhanced FcγRIIIa binding) leading to ADCC by NK cells and ADCP by macrophages, and also induces strong direct, caspase-independent cell death (with limited complement activation).
CD20×CD3 bispecific T-cell–engaging antibody that activates T cells to target and eliminate CD20-positive B cells.
Bispecific humanized antibody that binds CD20 on B cells and CD3 on T cells, cross-linking them to activate and redirect T cells to kill CD20-positive B cells via immune synapse formation and cytotoxic effector functions.
YES
DIRECT
Mosunetuzumab binds CD20 on target cells and CD3 on T cells, bringing them together to form an immune synapse and activate T cells to kill CD20+ cells via perforin/granzyme-mediated cytotoxicity.
Anti-HER2 antibody–drug conjugate delivering the topoisomerase I inhibitor DXd.
Humanized anti-HER2 monoclonal antibody linked to the topoisomerase I inhibitor DXd. Binds HER2 on tumor cells, is internalized, and releases DXd to inhibit Top1–DNA complexes, causing DNA damage, replication blockade, cell-cycle arrest, and apoptosis; also mediates ADCC and exerts a bystander killing effect due to a membrane-permeable payload.
YES
DIRECT
ADC binds HER2, is internalized, and releases the topoisomerase I inhibitor DXd, causing DNA damage and apoptosis; it also triggers ADCC and can induce bystander killing via a membrane-permeable payload.
CD20×CD3 bispecific T-cell–engaging antibody that activates T cells to target and eliminate CD20-positive B cells.
Bispecific humanized antibody that binds CD20 on B cells and CD3 on T cells, cross-linking them to activate and redirect T cells to kill CD20-positive B cells via immune synapse formation and cytotoxic effector functions.
NO
INDIRECT
Mosunetuzumab binds CD3 on T cells to activate them; the T cells then kill CD20+ B cells via immune synapse and perforin/granzyme release. CD3+ T cells are not the cytotoxic target.